KR20060118507A - 유기 화합물을 포함하는 조성물 - Google Patents

유기 화합물을 포함하는 조성물 Download PDF

Info

Publication number
KR20060118507A
KR20060118507A KR1020067010228A KR20067010228A KR20060118507A KR 20060118507 A KR20060118507 A KR 20060118507A KR 1020067010228 A KR1020067010228 A KR 1020067010228A KR 20067010228 A KR20067010228 A KR 20067010228A KR 20060118507 A KR20060118507 A KR 20060118507A
Authority
KR
South Korea
Prior art keywords
composition
weight
coat
hpmc
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020067010228A
Other languages
English (en)
Korean (ko)
Inventor
사비느 데쎄-브레떼
안드레아스 마이어
예르크 오고르카
쟝-삐에르 까시에르
아르멜르 데꾸
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20060118507A publication Critical patent/KR20060118507A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067010228A 2003-11-26 2004-11-25 유기 화합물을 포함하는 조성물 Withdrawn KR20060118507A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52537303P 2003-11-26 2003-11-26
US60/525,373 2003-11-26

Publications (1)

Publication Number Publication Date
KR20060118507A true KR20060118507A (ko) 2006-11-23

Family

ID=34632977

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010228A Withdrawn KR20060118507A (ko) 2003-11-26 2004-11-25 유기 화합물을 포함하는 조성물

Country Status (15)

Country Link
US (1) US20070218134A1 (https=)
EP (1) EP1689398A2 (https=)
JP (1) JP2007512287A (https=)
KR (1) KR20060118507A (https=)
CN (1) CN1905880A (https=)
AR (1) AR046458A1 (https=)
AU (1) AU2004292768B2 (https=)
BR (1) BRPI0417011A (https=)
CA (1) CA2546244A1 (https=)
MX (1) MXPA06005953A (https=)
MY (1) MY147202A (https=)
PE (1) PE20050588A1 (https=)
RU (1) RU2006122630A (https=)
TW (1) TW200534876A (https=)
WO (1) WO2005051346A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
CN102048701B (zh) * 2010-11-29 2013-01-09 青岛黄海制药有限责任公司 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法
US9399064B2 (en) * 2011-04-12 2016-07-26 Sawai Pharmaceutical Co., Ltd. Pitavastatin-containing preparation and method for producing same
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
WO2014129568A1 (ja) 2013-02-22 2014-08-28 ゼリア新薬工業株式会社 腸溶錠
KR102425303B1 (ko) * 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
IL319156A (en) * 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
CN111053752A (zh) * 2018-10-16 2020-04-24 南京卓康医药科技有限公司 一种稳定的匹伐他汀钙的肠溶片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
AU2002324715B2 (en) * 2001-08-16 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike

Also Published As

Publication number Publication date
EP1689398A2 (en) 2006-08-16
AU2004292768B2 (en) 2009-04-02
MY147202A (en) 2012-11-14
AR046458A1 (es) 2005-12-07
RU2006122630A (ru) 2008-01-10
CN1905880A (zh) 2007-01-31
TW200534876A (en) 2005-11-01
WO2005051346A3 (en) 2005-08-25
JP2007512287A (ja) 2007-05-17
PE20050588A1 (es) 2005-09-05
US20070218134A1 (en) 2007-09-20
MXPA06005953A (es) 2006-07-06
AU2004292768A1 (en) 2005-06-09
BRPI0417011A (pt) 2007-02-21
WO2005051346A2 (en) 2005-06-09
CA2546244A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
CN101090718B (zh) 3-羟基-3-甲基戊二酰辅酶a还原酶抑制剂和抗高血压剂的复合剂型及其制备方法
CA2740146C (en) Immediate release dosage forms of sodium oxybate
US6242003B1 (en) Organic compounds
CN108366957A (zh) 用于治疗心血管疾病的吉卡宾组合
KR20090034372A (ko) 옥시코돈을 포함하는 과립 및 경구 붕해 정제
JPH05246844A (ja) ＨＭＧ−ＣｏＡリダクターゼ禁止剤化合物を含んでなる安定化された製薬学的組成物
US20050239884A1 (en) Compositions comprising hmg-coa reductase inhibitor
US20060251720A1 (en) Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
NZ566872A (en) Pharmaceutical preparation having excellent photostability containing pitavastatin
MX2014007700A (es) Nueva combinacion.
KR20060118507A (ko) 유기 화합물을 포함하는 조성물
CN105431140B (zh) 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂
KR20070068658A (ko) 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
CA2529447A1 (en) Tablet comprising fluvastatin and carmellose calcium
KR20110097168A (ko) 고지혈증 치료용 약제학적 복합제제
MX2008007383A (en) Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor
NZ625506B2 (en) Compositions For Treatment of Heart Failure in Dogs.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid